Transplantation of CD34+ peripheral blood progenitor cells after high- dose chemotherapy for patients with advanced multiple myeloma

G. Schiller, R. Vescio, C. Freytes, G. Spitzer, F. Sahebi, M. Lee, Hua Wu Chun Hua Wu, J. Cao, J. C. Lee, C. H. Hong, A. Lichtenstein, M. Lill, J. Hall, R. Berenson, J. Berenson

Research output: Contribution to journalArticlepeer-review

259 Scopus citations

Abstract

A major potential problem of autologous transplantation in the treatment of advanced malignancy is the infusion of tumor cells. A multi-institutional study of purified CD34-selected peripheral blood progenitor cell (PBPC) transplantation was conducted in 37 patients with advanced multiple myeloma receiving myeloablative chemotherapy. Fourteen days after intermediate-dose cyclophosphamide, prednisone, and granulocyte colony-stimulating factor (G- CSF), a median of 3 (range, 2 to 5) 10-L leukaphereses yielded 9.8 x 108/kg (range, 3.7 to 28.3) mononuclear cells. The adsorbed (column-bound) fraction contained 5.9 x 108 cells/kg (range, 1.6 to 25.5) with 4.65 x 106 CD34 cells/kg (range, 1.2 to 23.3). Using Poisson distribution analysis of positive polymerase chain reactions with patient-specific complementarity- determining region 1 (CDR1) and CDR3 Ig-gene primers, tumor was detected in leukapheresis products from 8 of 14 unselected patients and ranged from 1.13 x 104 to 2.14 x 106 malignant cells/kg. After CD34 selection, residual tumor was detected in only three patients' products. Overall, a greater than 2.7- to 4.5-log reduction in contaminating multiple myeloma cells was achieved. CD34 PBPCs were infused 1 day after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg), and granulocyte-macrophage colony-stimulating factor was used until hematologic recovery. The median time to both neutrophil and platelet recovery was 12 days (range, 11 to 16 days and 9 to 52 days, respectively). The median number of erythrocyte and platelet transfusions was 7 (range, 2 to 37) and 3 (range, 0 to 85), respectively. Patients receiving fewer than 2 x 106 CD34 cells/kg had significantly prolonged neutropenia, thrombocytopenia, and an increased red blood cell and platelet transfusion requirement. Thus, CD34 selection of PBPCs markedly reduces tumor contamination in multiple myeloma and provides effective hematopoietic support for patients receiving myeloablative therapy.

Original languageEnglish (US)
Pages (from-to)390-397
Number of pages8
JournalBlood
Volume86
Issue number1
DOIs
StatePublished - 1995

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Transplantation of CD34<sup>+</sup> peripheral blood progenitor cells after high- dose chemotherapy for patients with advanced multiple myeloma'. Together they form a unique fingerprint.

Cite this